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A B S T R A C T
Liver MR is a well-established modality with multiparametric capabilities. However, to take advantage of its full
capacity, it is mandatory to master the technique and optimize imaging protocols, apply advanced imaging
concepts and understand the use of diﬀerent contrast media. Physiologic artefacts although inherent to upper
abdominal studies can be minimized using triggering techniques and new strategies for motion control. For
standardization, the liver MR protocol should include motion-resistant T2-w sequences, in-op phase GRE T1 and
T2-w fast spin echo sequences with fat suppression. Diﬀusion-weighted imaging (DWI) is mandatory, especially
for detection of sub-centimetre metastases. Contrast-enhanced MR is the cornerstone of liver MR, especially for
lesion characterization. Although extracellular agents are the most extensively used contrast agents, hepato-
biliary contrast media can provide an extra-layer of functional diagnostic information adding to the diagnostic
value of liver MR. The use of high ﬁeld strength (3T) increases SNR but is more challenging especially
concerning artefact control. Quantitative MR belongs to the new and evolving ﬁeld of radiomics where the use of
emerging biomarkers such as perfusion or DWI can derive new information regarding disease detection,
prognostication and evaluation of tumour response. This information can overcome some of the limitations of
current tests, especially when using vascular disruptive agents for oncologic treatment assessment. MR is, today,
a robust, mature, multiparametric imaging modality where clinical applications have greatly expanded from
morphology to advanced imaging. This new concept should be acknowledged by all those involved in producing
high quality, high-end liver MR studies.
1. Introduction
MR is a well-established liver imaging modality that has been
subject to continuous improvement, through advances in hardware,
software and contrast agent development [1,2]. It provides a compre-
hensive assessment of tissue characteristics through its multiparametric
capabilities, providing accurate qualitative and quantitative data [3,4].
When compared to its main competitor CT, MR has a higher
contrast-to-noise ratio (CNR), lack of ionizing radiation exposure and
uses contrast agents with the ability to explore both extracellular and
hepatocellular compartments [2,3,5].
There are however some constraints, like higher cost, longer
acquisition time, greater need for patient collaboration and individual
patient limitations, like claustrophobia, presence of pacemakers and
poor renal function, the latter speciﬁcally for contrast-enhanced MR
(DCE-MR) [5].
In order to use the abilities of liver MR to its full extent, performing
high quality eﬃcient exams, it is mandatory to use the best imaging
protocol, to optimize the technique, to minimize artefacts and to select
the most adequate type of contrast agent [4].
1.1. Patient preparation and positioning
Patients should receive general instructions regarding the magnetic
ﬁeld, highlighting the importance of immobilization throughout the
entire exam and the need for a shallow, regular breathing motion,
crucial for free-breathing and respiratory-triggering techniques [6,7].
Breath-hold acquisitions should also be explained at the beginning of
the exam [6]. Placing the patient in a comfortable supine position,
which may include knee support by a foam pad, is important for
immobilization and compliance to other instructions [6,7]. Placing an
abdominal cushion may be useful to minimize dielectric eﬀect observed
on 3T magnets [8,9].
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2. Standard liver protocols
An adequate MRI protocol has to be short, comprehensive and
standardized to allow reproducibility and consistency of image quality
and diagnostic information. It allows evaluation of the liver parench-
yma, vasculature and biliary system [2]. Examples of sequence para-
meters are displayed in Table 1.
2.1. Coil design
A body or torso phased array coil is available in almost all
manufactures and should be used for all sequences [4,6]. This type of
coil enhances signal-to-noise ratio (SNR), including the subcutaneous
fat signal, accentuating motion artefacts. To minimize these artefacts,
free-breathing sequences should be performed with fat suppression.
Phased array coils also permit the use of parallel imaging, which
improves scan time or resolution [6]. In obese patients, adequate coil
positioning can be checked by a scout sequence and repositioned if
needed [7].
2.2. Imaging planes
Single shot fast spin echo (SSFSE) images, performed at the
beginning of the exam, are obtained in the coronal and axial planes
[4,10]. They provide a valuable initial overview of the liver and upper
abdomen [6]. The remaining sequences of the standard liver protocol
are performed solely in the axial plane [4,10]. However, additional
coronal or sagittal images can be obtained when investigation of
anatomical relationships so warrants [6].
2.3. Artefact control
Despite all developments, MR diagnostic performance is still
aﬀected by artefacts, especially those caused by motion [2,7]. Measures
can be taken to avoid voluntary movements but physiologic motion is
inherent to any liver imaging protocol, whether it results from breath-
ing or cardiac motion, blood ﬂow and vessel pulsation or even
gastrointestinal peristalsis [6,11,12]. Movement during image acquisi-
tion leads to blurring and ghosting, image duplicates from misplaced
signal that may hamper image interpretation (Fig. 1) [6,7]. Strategies to
reduce motion artefacts include signal averaging; ultrafast motion-
resistant sequences, like HASTE, FLASH or TFE; and ubiquitous use of
fat suppression [6].
Breath hold, free breathing and respiratory triggering techniques
are used to control breathing motion, the last two leading to an increase
in scan time. The use of navigator echoes for respiratory triggering is
among the most popular and well succeeded techniques [4,6,12].
Cardiac motion aﬀects mostly the left liver lobe and can be
overcome by ECG or pulse triggering techniques, but again with an
acquisition time penalty [12].
To avoid blood ﬂow artefacts, presaturation bands and ﬂow
compensation techniques are the main strategies. Presaturation bands
are applied to the vessels above and below the target region and are
especially important for T1-weighted (T1-w) gradient echo (GRE)
sequences, like those used for the dynamic study. Flow compensation
or gradient moment nulling techniques only correct constant ﬂow.
Since they lead to an increase in echo time (TE), they are mainly
applied to T2-weighted (T2-w) sequences. The resulting brighter blood
vessels in the liver may mimic focal lesions when seen in cross section
[6,7].
Antispasmodic agents reduce motion artefacts from gastrointestinal
peristalsis, but they are not usually required for liver MR [6].
The standard use of multichannel, multielement phased array coils
has allowed the use of parallel imaging technique, which has drama-
tically improved SNR, accelerating the k-space acquisition, reducing
scan times and susceptibility artefacts. Acceleration factors, or the
number of lines of k-space acquired in parallel, are typically limited by
the development of residual artefacts and severe signal loss, thus, a
factor higher than 2 is rarely used [7,11,12]. Acronyms of parallel
imaging techniques include GRAPPA, SENSE and mSENSE [11].
Wraparound artefacts can occur when the ﬁeld of view is too small
regarding the size of the abdomen. They may occur in 3D techniques in
the slice direction or the phase encoding direction. These artefacts can
be corrected by increasing the ﬁeld of view, using pre-saturation bands
or using phase oversampling, although this last choice increases the in
scan time [4,7].
Field inhomogeneity caused by magnetic susceptibility due to air or
metal leads to local signal loss, distortion and inhomogeneous fat
suppression. GRE sequences are especially sensitive and decreasing TE
can assist in reducing these artefacts [7].
2.4. Basic sequences
2.4.1. SSFSE
Single Shot Fast Spin Echo (SSFSE) images are acquired in the
beginning of the liver MR protocol (Fig. 2A). Many authors recommend
Table 1
Sequence parameters for 1.5T.
Sequence Plane TR (ms) TE (ms) Flip angle Fat saturation Matrix FOV (mm) No. slices Slice thickness
HASTE coronal 900 77 150° none 256 × 243 400 40 5 mm
HASTE axial 900 77 150° none 256 × 218 400 44 5 mm
T2 TSE FS axial 1550 93 150° Fat sat 384 × 269 380 20 8 mm
T1 GRE in and out of phase axial 100 2.27
5.19
70° none 256 × 192 380 20 8 mm
Diﬀusion axial 2300 70 90° Fat sat 160 × 120 450 20 8 mm
T1 3D GRE VIBE axial 4.88 2.38 10° Fat sat 256 × 205 380 60 3 mm
T1 3D GRE VIBE hepatobiliary axial 4.88 2.38 30° Fat sat 256 × 205 380 60 3 mm
Fig. 1. T1-w fat sat sequence before intravenous contrast administration showing
examples of cardiac and respiratory motion artefacts, producing multiple ghost images
that reduce the diagnostic information.
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heavily T2-w images, with a TE greater than 160 ms, ideally
180–200 ms. These longer TEs can be useful for diﬀerentiating cysts
and hemangiomas from solid liver tumours [4,6,10]. The sequence has
a single excitation pulse, followed by a long series of 180° refocusing
pulses generating echo trains. It can be further accelerated by the
acquisition of half of the k space (HASTE sequence). These sequences
have consequently a greater resistance to susceptibility and motion
artefacts, since it takes one second or less to obtain each slice and one or
two breath-holds for the entire acquisition [4,13]. If two breath-holds
are required, a sequential acquisition should be performed to avoid
misregistration artefacts [4].
Soft tissue detail is generally blurry and there is considerable T2
decay from the long echo train [13]. Fat saturation (FS) is not
recommended for this sequence, since it obscures liver margins and
reduces the already relatively low overall signal [4].
2.4.2. T1
T1 sequences allow detection of fat and other substances with high
T1 signal, such as haemorrhage, high protein content and deposition of
copper or glycogen [2,4,14]. On the other hand, ﬂuid, a cellular or
ﬁbrotic content display a low signal on T1-w sequences [2].
GRE are generally used. These sequences are very sensitive to
susceptibility artefacts and therefore may assist in the detection of iron,
calcium, air or metal. Currently they are used to obtain a dual echo pair
of images, exploring the cancelation eﬀects of coexistent fat/water
molecules within the same imaging voxel. The TE should be the shortest
possible to reduce the T2* decay [2,4]. To prevent ambiguity from fat-
water interference or susceptibility, the out-phase TE should be lower
than the in-phase TE, usually 2.3 ms for out-phase and 4.6 ms for in-
phase imaging at 1.5T [4,8]. These sequences allow the detection of
intracellular fat, either in hepatic lesions or in the hepatic parenchyma
[2]. In the out-phase sequence, interfaces between tissues of diﬀerent
resonance frequencies (like pure fat and water) appear dark, creating
the so called india-ink artefact (Fig. 2C,D) [6,8].
3D sequences are increasingly being used, obtained with a modiﬁed
Dixon technique, which explores the chemical shift eﬀect of water and
fat, allowing to separate water and fat peaks contributing to better
image homogeneity, fat-cancelation, also providing thinner slice thick-
ness and slice overlap [4]. 3D GRE T1-w FS sequences (e.g. LAVA, VIBE,
THRIVE) are the typical sequences used for the dynamic contrast-
enhanced study [2,4].
2.4.3. T2
Fast/turbo spin echo (FSE/TSE) T2-w sequences are generally used,
with a repetition time (TR) in the range of 2500 ms and a TE of
60–120 ms, ideally 80–100 ms, leading to moderate T2 weighting
[2,4,6]. Since FSE T2-w sequences suﬀer from magnetization transfer
eﬀects that maintain the high signal intensity from abdominal fat, fat
suppression should be regularly applied (Fig. 2B) [6,13]. Fluid content
is the predominant information retrieved from this type of sequence,
allowing the distinction of solid from cystic-like focal lesions [2,4]. The
signal of the spleen should be used as the internal comparative signal
intensity since the majority of malignant lesions tend to display a
similar signal intensity [4].
Obtaining the T2 FS images after contrast administration is not only
possible but may even be advantageous, since the T2 shortening eﬀects
of gadolinium, reduces the baseline T2 signal intensity of the liver [4].
Short time inversion recovery sequences (STIR) are an alternative to
FSE T2 FS sequences. Focal lesions will display a higher CNR due to
profound fat signal suppression when the appropriate inversion time is
used (around 150 ms at 1.5T) and does not dependent on the fat
suppression homogeneity. As drawbacks they need longer acquisition
time, and possess lower SNR and less speciﬁc suppression, including for
blood or gadolinium-enhanced tissues. Therefore, STIR sequences
should not be obtained after contrast [4,6].
2.5. Diﬀusion weighted imaging
Diﬀusion is a physical process of random movement of water
molecules. This movement is restricted by cell membranes, resulting
in tissues with diﬀerent cellularity having diﬀerences in water mobility
[2,12]. A specialized MR tool, diﬀusion weighted imaging (DWI)
derives image contrast from these diﬀerences [5,11]. Highly cellular
tissues, like neoplasms, show restriction to diﬀusion and appear
hyperintense in DW images [2,12].
DWI has been increasingly applied to liver MR as an excellent
complementary tool for lesion detection and characterization, increas-
ing clinical conﬁdence and decreasing false positives [5,11,14].
Oncology is a major application of DWI, with a particular value in
the detection of liver metastases, especially sub-centimetre lesions
[11,12,14]. The role of DWI in distinguishing solid benign liver lesions
from malignant ones is more limited and generally requires additional
input from DCE-MR [5,14]. DWI may also help in predicting and
monitoring tumour response to treatment [5,12].
The interpretation of DW images can be done visually and quantita-
tively, through the apparent diﬀusion coeﬃcient (ADC) map [12,14].
Eco Planar Imaging (EPI) sequences are widely used for DWI, which
are basically T2-w images, acquired with single shot technique and FS.
They are essential to rapidly capture the diﬀusion signal before it
becomes null while also being relatively insensitive to patient motion
[6,11,12]. The TR should be greater than 2500 ms, at least 3 times the
T1 of a typical metastasis, to minimize T1 saturation eﬀects and
improve accuracy of ADC calculations. Image quality deteriorates
rapidly as TE increases, so it should be reduced, by decreasing the
acquisition matrix, which ends up to be lower than other sequences,
generally in the range of 128 × 128 [4].
Diﬀerent series of DW images are acquired through modiﬁcation of
the gradient strength and magnitude, referred as b-value (Fig. 3) [11].
One series should be obtained with a b-value of 0, meaning no
gradient is applied and consequently no diﬀusion information is
retrieved, giving similar information as T2 FS sequences [4,11].
Another series should be obtained with a low b-value (b< 100).
These are valuable for lesion detection, since there is a “black blood”
eﬀect, that improves conspicuity of lesions located near the dark vessels
[4,11,12]. Relatively to higher b-value images, they present greater
SNR and CNR and are less aﬀected by artefacts [12].
Series obtained with a high b-value (such as b = 800) are important
for liver lesion characterization [4]. In clinical practice, b-values higher
than 1000 s/mm2 are seldom used due to the relatively short T2-
relaxation time of the normal liver parenchyma [15].
EPI sequences are very sensitive to magnetic ﬁeld inhomogeneity
Fig. 2. A. HASTE sequence in the coronal plane. B. T2-w FS sequence. C,D. T1-w sequence
in phase and opposed phase, showing in this case loss of signal of the liver parenchyma in
the opposed phase acquisition (D), indicating fatty inﬁltration.
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and susceptibility artefacts, which lead to image degradation and
distortion. Causes include air-tissue interfaces, metal implants and
Nyquist ghosting from eddy currents produced by the rapidly switching
gradients [11,12]. SNR can be improved by increasing the ﬁeld strength
and by signal averaging [11].
The ADC map is the graphical representation of the ratio of DW
signal intensities and its measurements may discriminate between
benign and malignant lesions [12,14]. There may be also potential
roles in tumour grading and liver ﬁbrosis assessment [3,15]. The ADC
measurements are aﬀected by the sequence acquisition protocol and
suﬀer from a lack of reproducibility, particularly in respiratory trigger-
ing techniques, left liver lobe seated lesions, smaller size and lesion
heterogeneity [11,12,15]. Accurate estimation of ADC can be improved
by acquiring a large number of b-values, taking into consideration the
diﬀusion proﬁle of the speciﬁc tissue, which might be multiexponential
[11].
2.6. Contrast media administration
Appropriate detection and characterization of liver lesions requires
contrast-enhanced imaging, included in most liver MR protocols and
generally regarded as the most important sequences [4,10,14,16].
MR contrast agents in current clinical use are composed of
gadolinium (Gd) chelates [16]. These agents markedly shorten the T1
relaxation times and their eﬀects are observed in heavily T1-w
sequences [6]. Three-dimensional FS GRE T1-w sequences are the basis
for MR dynamic analysis, obtained before and through successive
phases after intravenous contrast administration [2,4]. These sequences
have suﬃcient temporal resolution to be performed in a single breath
hold, with good spatial resolution and SNR. Parallel imaging allows an
increase in spatial resolution or alternatively a decrease in acquisition
time [17].
The TR and TE of these sequences should be as short as possible. A
short TR allows for reduction in acquisition time and an increase in T1-
weighting, while a short TE minimizes susceptibility artefacts. Flip
angles typically vary between 10 and 15°.
Fat suppression is fundamental to improve visualization of liver
lesions, reducing the abdominal wall motion artefacts [4].
2.6.1. Extra-cellular agents
These are the best documented and most extensively used contrast
agents in liver MR [5,14]. They rapidly distribute throughout the
extracellular space and are excreted by glomerular ﬁltration, in a
manner similar to CT iodinated-contrast agents, allowing multi-phase
dynamic imaging [2,4,5]. In comparison to CT contrast agents, they
exhibit better enhancement of the blood pool on equilibrium phase and
better delineation of subtle areas of contrast accumulation due to a
paramagnetic ampliﬁcation eﬀect [10].
There are several formulations of extra-cellular Gd agents with
essentially the same pharmacologic and imaging characteristics [10].
About 10–20 mL of contrast are generally injected, with a dose of
0.1 mmol/Kg and an ideal ﬂow rate of 2 mL/s. Gadobutrol has twice the
concentration of other agents so it can be injected at 1 mL/s or
previously diluted. A 20 mL saline ﬂush after contrast injection is
recommended [6,16,18].
Precontrast images are important to characterize intrinsic lesion
properties (such as the presence of paramagnetic substances), and for
baseline comparison with postcontrast acquisitions and to assess the
technical quality before the dynamic imaging (Fig. 4A) [4,16]. The late
arterial phase, occurring 30 s after intravenous contrast injection, is
important for lesion and vascular assessment (Fig. 4B) [16,19]. Signs of
an adequate phase include presence of contrast in the hepatic artery
and early enhancement of the portal vein, with no or minimal liver
parenchymal enhancement [2,16]. To ensure adequate timing, a ﬁxed
delay or an individual delay can be applied, either with a test bolus or
using bolus tracking (CARE bolus software) [2]. The portal venous
phase, occurring 60–70 s after the injection, is important for detection
of hypovascular lesions and for characterization, looking up for
washout (Fig. 4C) [16,19]. A correct portal phase is characterized by
enhancement of the entire hepatic vasculature as well as strong liver
parenchymal enhancement [2,16]. The late venous or interstitial phase
is routinely performed in liver MR exams, acquired between 3 and
8 min after contrast media administration (Fig. 4D). This phase has
better depiction of the washout sign, and is also important for the
assessment of persistent enhancement of hemangiomas and delayed
enhancement of ﬁbrotic components in tumours, like cholangiocarci-
noma [2,5,16].
2.6.2. Hepato-biliary agents
These agents possess a variable degree of hepatic uptake and biliary
excretion, enabling the acquisition of an hepatobiliary phase which
may overcome some extracellular agents limitations and add diagnostic
value (Fig. 5) [2,10,16,19]. They oﬀer improved lesion detection and
characterization, as well as functional and biliary assessment
[1,5,10,14]. These Gd-based agents are biphasic agents, with both an
initial distribution phase into the extracellular space and a later
hepatobiliary phase [10,16,20]. The uptake and biliary excretion are
mediated by active transportation through cellular membrane trans-
porters in the hepatocytes, described as OATP B1/3 and MRP2 [1,2].
This only occurs in normal functioning hepatocytes, so hepatocellular
lesions conserving those properties will show T1-w enhancement in the
hepatobiliary phase, distinct from lesions lacking membrane receptors
Fig. 3. DW images acquired without gradient application (A; b value = 0), with a low b
value (B; b = 50) and with a high b value (C; b = 700). D − ADC map.
Fig. 4. T1 FS (VIBE) sequences before (A) and after intravenous extracellular Gd-based
contrast agent in the arterial phase (B), portal phase (C) and late venous phase (D).
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that appear hypointense compared to the normal parenchyma
[2,5,10,16].
There are two Gd-based hepato-speciﬁc agents, gadobenate dime-
glumine (Gd-BOPTA, Multihance®, Bracco Imaging, Milan, Italy) and
gadoxetic acid (Gd-EOB-DTPA, Primovist®, Bayer Schering Pharma AG,
Berlin, Germany), with diﬀerent proﬁles [14].
Gd-BOPTA has a recommended dose of administration of 0.1 mmol/
Kg and about 5% of the dose is excreted through the biliary tract
[1,14,16,20]. This agent has a better dynamic proﬁle than Gd-EOB-
DTPA, with higher enhancement of hepatic vascular structures
[1,2,18]. Hence, some authors prefer it when dynamic characterization
is more important [10,14]. The hepatobiliary phase is obtained 1–2 h
after administration and therefore does not interfere with washout
assessment [16].
On the other hand, Gd-EOB-DTPA has a recommended dose of
0.025 mmol/Kg and about 50% of the dose is excreted through the
biliary tract [1,14,16]. There is rapid uptake and the hepatobiliary
phase is obtained just 20 min after administration, when maximum
parenchymal enhancement is seen [14,16,20]. There is growing
evidence that in normal functioning livers a 10 min delay may suﬃce
[1,19]. Considering its pharmacodynamic proﬁle there is no true
interstitial phase but a transitional phase in which cellular contrast
retention already contributes to lesion enhancement [18]. The vascular
enhancement is lower and shorter in duration, compared to Gd-BOPTA
[14,18]. However, Gd-EOB-DTPA provides a stronger late hepatic and
biliary enhancement, due to its elimination proﬁle of 50% through the
biliary pathway [14,20].
Assessment of the biliary tree is also possible with these contrast
agents by performing a T1-w cholangiography in the hepatobiliary
phase [18,20]. Future applications of hepato-speciﬁc agents may
include ﬁbrosis staging and quantiﬁcation of liver function [19,20].
Some protocol adaptions need to be addressed when using these
agents. In the case of Gd-BOPTA, it implies that the patient has to be
scanned twice, while for Gd-EOB-DTPA, the hepatobiliary phase can be
obtained in the same examination [10]. Since a 10–20 min gap between
the initial dynamic imaging and the hepatobiliary phase still exists in
this case, imaging time can be ﬁlled with sequences unaﬀected by the
presence of the contrast agent, such as T2-w FS and DWI [1,14,19]. GRE
in and out of phase images and MRCP should, on the other hand, be
performed before contrast administration [4,10,14]. Regarding the
hepatobiliary phase, an increase in the ﬂip angle to 30−35° increases
the signal of the enhancing liver and biliary tree and reduces the signal
of non-enhancing structures, improving the conspicuity of hypointense
lesions [1,19].
3. Liver MR at 1.5T and 3T
Scanners operating at a 3T magnetic ﬁeld have been introduced and
rapidly evolved over the last decade. These scanners take advantage of
the increased SNR provided by 3T ﬁelds relative to 1.5T, which is used
to improve spatial resolution, to lower the acquisition time or a
combination of the two [8,11,17].
In most tissues, T1 relaxation times are generally longer at 3T
compared to 1.5T, while T2 relaxation times are almost unaﬀected.
There is also greater fat and water spectral separation, which can lead
to better fat suppression [8,21].
The longer T1 relaxation times at 3T require longer TRs in T1-w
sequences, with a consequent increase in acquisition time, in order to
be equivalent to 1.5T sequences [9]. Acquisition time is however
limited by the breath-hold technique. An inversion recovery prepara-
tory pulse can be added to increase T1 contrast or parallel imaging can
be employed to reduce acquisition time [8].
Echo sampling for in-phase and out-phase imaging also suﬀers
changes, since the precession frequencies of water and fat are reduce to
half at 3T. With this magnetic ﬁeld strength, the shortest out-phase and
in-phase TEs are 1.15msec and 2.3msec, respectively [8,9]. T2
sequences are generally acquired with a shorter TE to compensate for
the greater T2* decay at 3T [9].
The dynamic study is one of the MR parameters that draw greatest
beneﬁts from a higher ﬁeld strength. This is due to the substantial
increase in liver tissue T1 relaxation times but minimal changes for T1
Gd shortening eﬀects, leading to a higher liver-to-lesion contrast [17].
Higher SNR can be used to improve image resolution, using thinner
slices, or reduce scan time, which is important for diﬃcult patients [8].
The quality of the dynamic study can be further improved by a Dixon
method of fat suppression [21]. Regarding DWI, there can be an up to
two-fold increase in SNR [11,12].
Nevertheless, performing exams with a 3T magnetic ﬁeld also has
disadvantages [17]. Firstly, regarding patient preparation, 3T compat-
ibility of medical devices should be interrogated, since 1.5T compat-
ibility is not suﬃcient [8].
There is greater radiofrequency power deposition to the patient at
3T relatively to 1.5T, especially in T2-w FSE sequences due to the larger
number of radiofrequency pulses [21]. Energy deposition can be
reduced by increasing the TR, reducing transmitter bandwidth, redu-
cing the anatomical coverage, decreasing ﬂip angles, using radio-
frequency refocusing techniques or parallel imaging [8,9,21].
The higher ﬁeld strength leads to greater magnetic susceptibility
artefacts, with image distortion and signal loss but also greater
conspicuity of metal or gas [8,9,11].
Standing wave or dielectric artefact becomes a concern at 3T, with
interactions between radiofrequency waves and the patient’s body
leading to heterogeneous deposition and large variations in signal
[8,17,21]. FSE sequences, like T2-w sequences, are more aﬀected,
demonstrating areas of signal drop, especially in the left liver lobe,
particularly in larger patients and in the presence of ascites (Fig. 6).
Although abdominal pads between the patient’s body and the coil may
partially reduce these artefacts, they are now more consistently
prevented by hardware improvements like dual source parallel radio-
frequency transmission [8,9,21]. Alternatively, obese patients or pa-
tients with known ascites should preferably undergo 1.5T MR [21].
Chemical shift misregistration artefact occurring in fat-water inter-
faces also increases with the increasing ﬁeld strength. It can be reduced
by decreasing the receiver bandwidth, swapping frequency and phase
encoding directions, and is eliminated with the use of fat suppression
[4].
Greater sensitivity to susceptibility artefacts and ﬁeld inhomogene-
ity lead to higher distortions in EPI sequences used in DWI and
incomplete fat saturation. There are also reported signiﬁcant diﬀer-
ences between ADC measurements performed at 1.5 and 3T [12]. Some
of these limitations may be reduced by the use of parallel imaging [8].
Fig. 5. T1 FS (VIBE) sequence after intravenous Gd-EOB-DTPA administration in the
hepatobiliary phase, with enhancement of the liver parenchyma and contrast in the
biliary tree.
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4. Advanced liver MR protocols
4.1. Perfusion MR
In recent years there has been an increasingly wide use and
development of vascular targeting agents, such as antiangiogenic drugs
and vascular disruption agents (VDAs), for clinical use in the treatment
of cancer as well as in clinical trials [22–25]. Considering the cytostatic
nature of vascular targeting agents it has been suggested that the eﬀect
of vascular targeting therapies may be better assessed by evaluating the
functional changes in tumour tissue than by observing the changes in
tumour size alone [22,26]. Assuming this premise, multiparametric MR
imaging can be a promising tool. In particular, DCE-MR has seen
increased use in clinical trials of several antiangiogenic drugs and
VDAs, as it can be used to investigate microvascular structures and their
function, both noninvasively and quantitatively [22,23].
DCE-MR images are obtained by the venous injection of a low
molecular weight Gd chelate at a constant rate. Within the tumour
tissue, these agents extravasate from intravascular to the extravascular
extracellular space (EES), which results in T1-w signal increase [27,28].
The rate of contrast agent extravasation to EES in the tumour tissue is
determined by vessel leakiness and blood ﬂow. Therefore, the signal
measured in DCE-MR imaging represents a combination of permeability
and perfusion [27]. DCE-MR is sensitive to alterations in vascular
permeability, extracellular space, and blood ﬂow. To ideally record the
signal change in the supplying blood vessel and within the tumour, a
fast injection rate of the contrast agent captured with high temporal
resolution is required [27,29]. This signal enhancement of liver
perfusion can be quantiﬁed either using a semi-quantitative or quanti-
tative analysis. The semi-quantitative analysis is based on the calcula-
tion of parameters that can be extracted from time-signal intensity
curves. The quantitative analysis needs computational-based curve
cutting algorithms using a bi-compartmental model with arterial input
function [27]. The parameters from both analysis methods have been
shown to present correlation with tumoural angiogenesis [29].
With the semi-quantitative analysis, diﬀerent parameters that
characterize the shape of the normalized signal intensity (SI)-time
curve can be extracted: (1) area under curve (AUC): expresses the
amount of enhancement over a deﬁned period of time (usually from
starting increment of the SI-time curve to 60 or 90 s); (2) maximum of SI
or peak enhancement ratio (SI maximum-SI baseline/SI baseline) of the
enhancing curve; (3) wash-in slope: determines the velocity of enhance-
ment. It is calculated as the maximum change in enhancement per unit
time, usually from 20% to 80% range of the increment curve; and (4)
mean transit time (MTT): represents the mean time for blood to perfuse a
region of tissue and is aﬀected by the blood volume and blood ﬂow in
the region under analysis [27,28]. Although widely used, the semi-
quantitative analysis is highly aﬀected by the gain factor of the
acquisition systems, contrast media volume and injection rate, because
the true concentration of contrast agent in the tissues is not estimated.
Thus, diﬀerences in temporal resolution and injection rates can easily
change the shape of SI curves, making comparison and quantiﬁcation
diﬃcult [29,30], not allowing a true physiologic insight into the
behaviour of tumour vessels. Quantitative analysis is based on model-
ling the concentration change of the contrast agent using pharmacoki-
netic modelling techniques. An initial conversion step of SI to concen-
tration values is needed. Concentration vs time curves are then ﬁtted
using a bi-compartmental model (vessels and EES) with two vascular
inputs (aorta and portal vein) [28–30]. Thus, the following parameters
can be extracted from a mathematical model: (1) Ktrans (forward
volume transfer constant): determines the inﬂux of the contrast agent
from the intravascular space to the EES. It predominantly represents
vascular permeability in a permeability-limited (high ﬂow) situation,
but also represents the blood ﬂow into the tissue in a ﬂow-limited
situation; (2) Kep (reverse reﬂux rate constant): expresses the return
process of the contrast agent from the EES to the intravascular space;
and (3) Ve (volume fraction of EES): an indirect measure representing
the cellular density of the tissue [27,30]. In comparison to the semi-
quantitative analysis, these parameters require additional calculations
to generate parametric maps obtained after a pixel-by-pixel curve
ﬁtting process of the region under analysis, being more time consuming
and computationally demanding. After generating parametric maps
(Fig. 7), the mean or median values within region of interest are usually
calculated to represent tumour microvasculature, but histogram analy-
sis (Fig. 8) or heterogeneity in parametric maps may also provide
additional information [27,30]. Throughout the years, numerous
pharmacokinetic models have been proposed by Tofts et al., Brix
et al. and Larsson et al. [31–33], using a single arterial input function
[27]. Since hepatocellular carcinoma receives major blood supply from
hepatic arteries, this single input model is frequently used in the
literature. On the other hand, for parenchymal and metastatic disease,
in which arterial and portal vein supply is present, the dual input one
compartment model proposed by Materne et al. [34] is more appro-
priate.
Regarding technical details, the protocol includes a T1-w 3D spoiled
GRE technique using variable ﬂip angles. Compared with 2D imaging
sequences, the 3D technique eliminates inaccuracies due to the radio-
frequency excitation pulse proﬁle, and also has the advantage of better
SNR [30]. Adequate T1 mapping is necessary for quantitative analysis
and this is usually achieved with diﬀerent ﬂip angles, as suggested by
Wang et al. [35]. In order to track liver perfusion reliably, MRI of the
liver should employ a high temporal resolution technique (i.e. repeated
Fig. 6. Example of dieletric artefact in a T2-w FS sequence obtained with a 3T magnetic
ﬁeld in an obese patient with ascites, with dramatic signal drop in the center of the image.
Fig. 7. Representative DCE-MR imaging parametric ktrans maps fused with T2 coronal
images in a patient with advanced hepatocellular carcinoma. Red areas correspond to
higher tumour vascularity and hence higher Ktrans values. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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imaging of the same area in the liver about every 4 s), in a scan plane
that shows the lesion or area of interest. Ideally, the aorta and the portal
vein should be included in the same image sections. Hence, an oblique
imaging plane aﬀorded by the MRI technique can be particularly
helpful to ensure all these structures are included [30]. The signal
intensity changes within these structures, together with the T1 calibra-
tion maps, are used to derive the Gd contrast concentration-time curves
in the liver and tumours. One of the challenges in acquiring high quality
liver perfusion MRI is respiratory motion, which can substantially
degrade image quality. Therefore, imaging in quiet superﬁcial breath-
ing has been suggested to minimize these eﬀects. An example of a liver
perfusion MR protocol for use in a commercial scanner is described in
Table 2 [30].
4.2. Quantitative MR for diﬀuse liver diseases: fat, iron and ﬁbrosis
Liver steatosis is the hallmark of non-alcoholic liver disease
(NAFLD), but is also a common feature in several diﬀuse liver diseases.
Liver iron concentration (LIC) is used as a surrogate of body iron stores
in patients with primary and secondary hemochromatosis.
Nevertheless, iron deposition is also present in diﬀerent diﬀuse liver
diseases. Chronic liver injury results in liver ﬁbrosis and, consequently,
can lead to liver cirrhosis. Because liver biopsy is invasive and has
several limitations, advanced MR imaging techniques have emerged as
non-invasive quantitative biomarkers for fat and iron deposits, and
assessment of liver ﬁbrosis.
4.2.1. MR quantiﬁcation of hepatic fat (proton density fat fraction)
MR spectroscopy (MRS) is considered the imaging gold-standard for
fat quantiﬁcation. Knowing a priori the resonance frequencies of fat and
water protons, their concentrations can be quantiﬁed directly from
their spectral signal [36]. Fat (triglyceride) signal has multiple fre-
quency components, the dominant one being located at a frequency
shift of 420 Hz (1.46 ppm) relative to water peak, on 3T magnetic ﬁled.
Fat proton density results from the sum of these diverse multiple fat
peaks. MRS is an accurate and reproducible method for quantiﬁcation
of proton density fat fraction (PDFF) [36]. However, it is time
consuming and it is only available in specialized hospital or research
centres.
Multi-echo chemical shift encoded (MECSE) GRE sequences, per-
formed with more than 3 echoes (usually between 6 and 12), have
recently emerged as an accurate tool for PDFF quantiﬁcation [36,37]
(Fig. 9). These sequences take advantage of the chemical shift of water
and fat protons. For precise fat quantiﬁcation, these sequences must be
corrected for the main confounding factors (T1 bias, eﬀect of T2*
relaxation, fat spectral complexity) [36,37]. Fat protons have a shorter
T1 relaxation time than water protons, which may introduce a
signiﬁcant bias in fat fraction estimation if the acquisition is T1-w.
This “T1 bias” can be minimized using a low ﬂip angle (< 10°) [38].
The ﬁtting model should also incorporate the multiple frequencies of fat
spectrum (multipeak fat spectral modelling) [36,37,39]. The eﬀect of
T2* decay between diﬀerent echoes confounds PDFF quantiﬁcation,
mainly when concomitant iron deposition is present, but also in normal
Fig. 8. Representative ROI tracing in T2 image and corresponding total volume histogram
analysis of the ktrans parameter in same patient as mentioned in Fig. 7.
Table 2
Illustrative example of a perfusion MRI sequence performed in a 1.5T scanner (adapted
from Thng et al).
MRI platform 1,5T
Type of pulse sequence 3D FLASH
TR 2.72 ms
TE 1 ms
Partition thickness 8 mm
Slices per slab 10
Matrix 256 × 169
Phase encode direction Anterior to posterior




Flip angle before contrast 2° and 14°
Flip angle after contrast 14°
Bandwidth 490Mhz
RF spoiling Yes
Temporal resolution 1.98 s per slab of 10 slices
Precontrast scans 10 measurements of each ﬂip angle averaged for
calculation of native T1
Gadolinium injection 0.2 mmol/kg at 3 mL/s followed by 20 mL ﬂush
Patient respiration Quiet breathing
Post contrast scans A total of 180 consecutive measurements. Inject
contrast only when the 20th measurement has been
completed
Scan sections to use for
processing
Center 6 image sections only
Fig. 9. Fat (PDFF) and iron (R2*) quantiﬁcation using MECSE-MR sequence, in male
patient with non-alcoholic fatty liver disease. (a) Magnitude images used for fat and iron
quantiﬁcation, and the respective signal decay curve calculated with QLiver® software
(QUIBIM SL, Valencia, Spain). A ROI area in the right hepatic lobe determined a
PDFF = 16% and R2* = 162 s-1. Steatosis and iron overload frequently co-exist in
diﬀuse liver diseases. (b) Parametric maps of PDFF (c) and iron related-R2* (d)
measurements are useful to demonstrate the distribution and the amount of fat and iron
throughout the liver parenchyma.
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livers. The signal ﬁtting model of the multiple echoes allows to quantify
fat and to estimate the T2* decay. The T2* estimation is used to correct
the eﬀect of T2* in PDFF quantiﬁcation. Moreover, because liver T2* is
related to the amount of iron deposition, it can also be used for
simultaneous quantiﬁcation of iron deposits [36,40–42]. Nevertheless,
because large iron content lead to extremely low signal in GRE
sequences, PDFF measurements may be corrupted in livers with severe
iron overload [41].
Fat measurements can be performed in parametric maps, which
have the advantage to demonstrate not only the amount but also the
distribution of fat throughout the liver parenchyma (Fig. 9). PDFF
quantiﬁcation can be performed with commercially available tools
(IDEAL-IQ®, GE; mDIXON Quant®, PHILIPS), or using in-house devel-
oped software. MECSE-MR imaging sequences are accurate for quanti-
ﬁcation of hepatic steatosis [41,43,44], being repeatable [45] and
reproducible across diﬀerent MR scanner platforms at 1.5T and 3T
scanners [46].
4.2.2. MR quantiﬁcation of hepatic iron overload
The most traditionally used method for quantiﬁcation of liver iron
concentration (LIC) uses 5 diﬀerent IP GRE sequences and compares the
signal intensity between the liver and a non-overloaded reference tissue
(paraspinal muscles) [47]. However, these ratio measurements are
biased by coexisting hepatic steatosis and/or muscle fatty inﬁltration.
Furthermore, this method is not compatible with phase-array coils and
is not calibrated for 3T equipment.
Relaxometry methods, on the other hand, use a series of images
acquired with increasing TE, either with a SE or a multi-echo GRE
sequence, and they can be performed with surface coils. The liver signal
intensity is modelled as a function of TE and ﬁtted to either a mono-
exponential or bi-exponential decay model, calculating signal decay
constants (T2 or T2*) or signal decay rates (R2 or R2*) [48]. Liver T2
and T2* (or R2, R2*) are closely related to LIC, and can be used in
clinical practice as surrogates of LIC, provided that they are calculated
with validated acquisition and analysis protocols [49].
A R2 relaxometry method [50] is currently available as a commer-
cial service (FerriScan®). Five T2-w sequences are acquired during free-
breathing, and images are forwarded for centralized image data
analysis and R2 measurements. R2 techniques are less sensitive to
external magnetic inhomogeneities [48] but require a longer acquisi-
tion time than R2* techniques, being more prone to motion artefacts.
R2* relaxometry methods are usually performed with SPGR multi-
echo sequences, during one or two breath-hold acquisitions [42,48,51].
T2* or R2* measurements can be calculated using commercial post-
processing software (CMR Tools®) or in-house developed software. The
ﬁrst echo should be as short as possible (1 ms or less) and the echo
spacing should be short enough (approximately 1 ms or less) [42], to
guarantee that the signal decay is captured even in high iron-loaded
livers. The LIC (mg Fe/g or μmol Fe/g) can be estimated from the R2*/
T2* measurements, using calibration curves that were pre-validated
against liver biopsies [42,48,51,52]. As mentioned above, MECSE-MR
sequences, the same as described for fat quantiﬁcation, can also be used
for R2* estimation and LIC quantiﬁcation (Figs. 9 and 10) [40–42,48]
while simultaneously assessing the liver fat content (Figs. 9 and 10).
Nevertheless, relaxation rates are dependent on magnetic ﬁeld strength
and imaging acquisition parameters, and R2* relaxometry still needs
technical standardization and consensus [42].
4.2.3. MR quantiﬁcation of hepatic ﬁbrosis
MR elastography (MRE) evaluates liver stiﬀness, measuring the
speed of shear waves propagating through the liver, which are induced
by a vibrating compression device [53]. Then, using a phase-contrast
MR sequence with motion-encoding gradients, these shear waves are
detected and converted in quantitative maps (elastograms) of tissue
stiﬀness (measured in kPa). MRE can be implemented on a conven-
tional MR system, using modiﬁed GRE or SE sequences and adding
hardware to generate the waves and software for acquisition and
processing. Liver stiﬀness is directly related to the stage of ﬁbrosis,
increasing with the progression of the disease [53,54]. MRE has a high
sensitivity and speciﬁcity in diagnosing and staging of liver ﬁbrosis and
it is now considered as the best non-invasive tool to assess liver ﬁbrosis
[53]. Nevertheless, besides ﬁbrosis, hepatic stiﬀness also increases with
liver inﬂammation. Furthermore, MRE is impaired in patients with
moderate to severe iron overload [55], but this limitation might be
overcome by using modiﬁed SE techniques [56]. In comparison with
ultrasound elastography methods, MRE has the advantage to analyse a
larger volume of liver parenchyma, evaluating the whole liver, and not
be limited by obesity or ascites [53].
A T1 mapping technique has also been recently purposed for the
evaluation and scoring of liver ﬁbrosis [57]. T1 relaxation time map is
obtained using a single breath-hold Shortened Modiﬁed Look Locker
Inversion recovery (shMOLLI) sequence, in the axial plane through the
right lobe of the liver and the spleen [57]. T1 values need to be adjusted
for the hepatic iron level, because iron accumulation in the presence of
ﬁbrosis can mimic normal T1 values. This method has demonstrated a
good correlation with histological stage of liver ﬁbrosis and it seems
promising in predicting negative clinical outcomes in patients with
chronic liver disease [58].
DWI and intra-voxel incoherent motion (IVIM) DWI MR imaging
have also been proposed for assessment of liver ﬁbrosis: livers with
higher ﬁbrosis stages would have lower ADC values and lower
perfusion related IVIM parameters than livers without ﬁbrosis [59].
However, ADC and IVIM measurements are not accurate enough to be
used in clinical practice for staging liver ﬁbrosis, in diﬀuse liver
diseases [60]. Also, its use has been limited by the large variability in
the cut-oﬀ values and by the possible confounding eﬀect of hepatic
steatosis [60,61] or iron overload [61].
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Fig. 10. Iron (R2*) quantiﬁcation using MECSE-MR sequence, in male patient with
hereditary hemochromatosis, in two diﬀerent time points. Magnitude images from a
MECSE MR sequence acquired with 12 diﬀerent TEs, used for R2* quantiﬁcation, and the
respective signal decay curve, calculated with QLiver® software (QUIBIM SL, Valencia,
Spain). (a) MR examination in 2013 demonstrates low signal intensity of liver
parenchyma, which is related to severe iron overload. A plot of mean signal intensity
within a circular ROI is modeled as a function of TE, as a bi-exponential decay curve.
Estimated R2* is 804s-1. (b) In 2015, after intensive treatment with phlebotomies and
removal of 3,85 g total body iron stores, the liver R2* is 51 s-1. These measurements can
be used for follow up of patients with iron overload disorders.
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